^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             39    10631001 10631002 10631003    
                           11601002 11601006 11601007    
                           13031001 13031004 13581001    
                           13581010 13581014 13991001    
                           13991002 13991004 13991007    
                           13991009 13991010 16591001    
                           16591003 16591006 17601002    
                           17601003 17601005 17601007    
                           17601012 17601014 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731004 19731006 19831001    
                           19831005 19831008 19901003    
      AVISITN         4    1 4 8 12                      
      trtn            3    1 2 3                         
      SSNRISN         2    1 2                           
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      wk12            2    0 1                           


                          Dimensions

              Covariance Parameters            10
              Columns in X                     39
              Columns in Z                      0
              Subjects                         39
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read             129
          Number of Observations Used             129
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Number of Observations

          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       303.90933895                
          1              2       249.50979071      0.06474871
          2              1       248.03400648      0.01060314
          3              1       247.81629350      0.00049493
          4              1       247.80695576      0.00000149
          5              1       247.80692846      0.00000000


                   Convergence criteria met.                    
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.5016
                UN(2,1)     id           0.2540
                UN(2,2)     id           0.5949
                UN(3,1)     id           0.3240
                UN(3,2)     id           0.5938
                UN(3,3)     id           1.0529
                UN(4,1)     id           0.3563
                UN(4,2)     id           0.3363
                UN(4,3)     id           0.6023
                UN(4,4)     id           0.6406


                        Fit Statistics

             -2 Res Log Likelihood           247.8
             AIC (Smaller is Better)         267.8
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             AICC (Smaller is Better)        269.9
             BIC (Smaller is Better)         284.4


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         56.10          <.0001


                 Type 3 Tests of Fixed Effects
 
                           Num     Den
     Effect                 DF      DF    F Value    Pr > F

     BASE                    1    31.2      47.76    <.0001
     trtn                    2    29.6       0.85    0.4392
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                           Num     Den
     Effect                 DF      DF    F Value    Pr > F

     wk12                    1    21.1       1.53    0.2304
     SSNRISN                 1      30       2.98    0.0948
     BASE*wk12               1    20.7       0.54    0.4717
     trtn*SSNRISN            2    29.5       1.70    0.2000
     trtn*wk12               2    21.3       1.43    0.2610
     SSNRISN*wk12            1    21.5       1.75    0.2000
     trtn*SSNRISN*wk12       2    21.3       1.91    0.1725


 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                       Concomitant
                       Use of
                       SSRI/SNRI                Standard
 Effect         trtn   (N)           Estimate      Error     DF

 trtn*SSNRISN   1      1              -0.6264     0.5062   31.3
 trtn*SSNRISN   1      2              -0.7888     0.2542   26.8
 trtn*SSNRISN   2      1              -0.6615     0.4760   27.2
 trtn*SSNRISN   2      2              -0.7735     0.1892   29.8
 trtn*SSNRISN   3      1               0.4232     0.5317   30.2
 trtn*SSNRISN   3      2              -0.9677     0.2036   30.6

 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                      Concomitant
                      Use of
                      SSRI/SNRI
Effect         trtn   (N)           t Value   Pr > |t|    Alpha

trtn*SSNRISN   1      1               -1.24     0.2252     0.05
trtn*SSNRISN   1      2               -3.10     0.0045     0.05
trtn*SSNRISN   2      1               -1.39     0.1759     0.05
trtn*SSNRISN   2      2               -4.09     0.0003     0.05
trtn*SSNRISN   3      1                0.80     0.4323     0.05
trtn*SSNRISN   3      2               -4.75     <.0001     0.05

 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                          Concomitant
                          Use of
                          SSRI/SNRI
    Effect         trtn   (N)              Lower       Upper

    trtn*SSNRISN   1      1              -1.6585      0.4057
    trtn*SSNRISN   1      2              -1.3106     -0.2670
    trtn*SSNRISN   2      1              -1.6378      0.3147
    trtn*SSNRISN   2      2              -1.1600     -0.3869
    trtn*SSNRISN   3      1              -0.6624      1.5087
    trtn*SSNRISN   3      2              -1.3832     -0.5523
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             23    10631001 10631002 10631003    
                           11601002 11601006 11601007    
                           13031001 13581001 13581010    
                           13581014 13991002 13991004    
                           13991007 13991009 16591001    
                           17601005 17601007 17601014    
                           17661004 19731002 19731006    
                           19831001 19901003             
      AVISITN         4    1 4 8 12                      


                          Dimensions

              Covariance Parameters            10
              Columns in X                     10
              Columns in Z                      0
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Subjects                         23
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read              76
          Number of Observations Used              76
          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       189.77886667                
          1              2       156.83106706      0.00804854
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          2              1       156.67058722      0.00039938
          3              1       156.66325617      0.00000144
          4              1       156.66323056      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.6484
                UN(2,1)     id           0.3537
                UN(2,2)     id           0.8062
                UN(3,1)     id           0.4138
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(3,2)     id           0.8081
                UN(3,3)     id           1.3104
                UN(4,1)     id           0.4123
                UN(4,2)     id           0.4466
                UN(4,3)     id           0.6893
                UN(4,4)     id           0.6752


                        Fit Statistics

             -2 Res Log Likelihood           156.7
             AIC (Smaller is Better)         176.7
             AICC (Smaller is Better)        180.7
             BIC (Smaller is Better)         188.0
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         33.12          0.0001


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1    17.9      21.26    0.0002
    trtn1                     1    17.1       0.11    0.7457
    wk12                      1    11.6       2.75    0.1240
    SSNRISN1                  1    16.9       2.54    0.1294
    BASE*wk12                 1    11.6       0.40    0.5390
    trtn1*SSNRISN1            1    16.5       0.77    0.3923
    trtn1*wk12                1    11.5       2.07    0.1768
    wk12*SSNRISN1             1    11.6       0.06    0.8146
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    trtn1*wk12*SSNRISN1       1    11.6       0.12    0.7381


                           Estimates
 
                              Standard
Label               Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO  Week 4    -0.9615    0.8482  16.3    -1.13    0.2734
2 ACT-PBO  Week 4    -0.1286    0.3901  17.1    -0.33    0.7457
1 ACT-PBO  Week 12   -0.7911    1.0459  15.3    -0.76    0.4609
2 ACT-PBO  Week 12    0.3513    0.4396  14.1     0.80    0.4375

 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
       Label                Alpha       Lower       Upper

       1 ACT-PBO  Week 4     0.05     -2.7571      0.8342
       2 ACT-PBO  Week 4     0.05     -0.9512      0.6941
       1 ACT-PBO  Week 12    0.05     -3.0169      1.4347
       2 ACT-PBO  Week 12    0.05     -0.5912      1.2939


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1   16.5      0.77
 Treatment*Week 12*Subgroup Interaction      1     15      1.00

 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.3923
        Treatment*Week 12*Subgroup Interaction   0.3325
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             30    10631001 10631003 11601002    
                           11601006 13031001 13031004    
                           13581001 13581010 13581014    
                           13991001 13991010 16591003    
                           16591006 17601002 17601003    
                           17601007 17601012 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731004 19731006 19831001    
                           19831005 19831008 19901003    
      AVISITN         4    1 4 8 12                      


 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Covariance Parameters            10
              Columns in X                     10
              Columns in Z                      0
              Subjects                         30
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read              96
          Number of Observations Used              96
          Number of Observations Not Used           0


 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       231.19554630                
          1              2       196.78778132      0.30998756
          2              1       189.09077759      0.16609259
          3              1       185.83217190      0.06621394
          4              1       184.70087732      0.01609382
          5              1       184.45299509      0.00136358
          6              1       184.43393197      0.00001255
          7              1       184.43376535      0.00000000


                   Convergence criteria met.                    


 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.4620
                UN(2,1)     id           0.2824
                UN(2,2)     id           0.6559
                UN(3,1)     id           0.4746
                UN(3,2)     id           0.6995
                UN(3,3)     id           1.2839
                UN(4,1)     id           0.4355
                UN(4,2)     id           0.4394
                UN(4,3)     id           0.8417
                UN(4,4)     id           0.8198


                        Fit Statistics

             -2 Res Log Likelihood           184.4
             AIC (Smaller is Better)         204.4
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             AICC (Smaller is Better)        207.4
             BIC (Smaller is Better)         218.4


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         46.76          <.0001


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1    23.3      43.60    <.0001
    trtn2                     1    23.5       0.44    0.5116
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    wk12                      1      15       4.81    0.0444
    SSNRISN1                  1    21.7       5.86    0.0243
    BASE*wk12                 1    15.1       0.93    0.3504
    trtn2*SSNRISN1            1      22       6.34    0.0196
    trtn2*wk12                1    15.1       0.28    0.6046
    wk12*SSNRISN1             1    14.6       0.14    0.7181
    trtn2*wk12*SSNRISN1       1    15.9       1.82    0.1959


 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
                               Standard
Label                Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO    Week 4   -1.6836    0.6947  21.6    -2.42    0.0242
2 ACT-PBO  Week 4      0.1784    0.2677  23.5     0.67    0.5116
1 ACT-PBO  Week 12    -0.5750    0.9247  21.4    -0.62    0.5406
2 ACT-PBO  Week 12     0.3154    0.3500  20.4     0.90    0.3779

                           Estimates
 
      Label                 Alpha       Lower       Upper

      1 ACT-PBO    Week 4    0.05     -3.1258     -0.2414
      2 ACT-PBO  Week 4      0.05     -0.3747      0.7315
      1 ACT-PBO  Week 12     0.05     -2.4962      1.3461
      2 ACT-PBO  Week 12     0.05     -0.4137      1.0446
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1     22      6.34
 Treatment*Week 12*Subgroup Interaction      1   21.4      0.81

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.0196
        Treatment*Week 12*Subgroup Interaction   0.3773
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
